Acquired Company’s Value Chain Question: Strategic Management Class
Discussion Week 8
Using a recent acquisition, what areas of the acquired company’s value chain will add to the acquirer’s core competencies?
———————————————————————————————————————
Here are a couple of examples from students posts. Please do not use the same ones. And also please use a United States based example
Discussion: Amazon acquisition of Whole Foods and Amazon
Amazons acquisition of Whole Foods gives Amazon a lot of leverage in the grocery business. Whole Foods specialty market contain locations throughout the US and Canada. Amazons acquisition adds value in a brand, Whole Foods private label 365. The acquisition adds product differentiation to Amazons line of private labels. Since the acquisition, Amazon has already lower price and added products that wasnt in Whole Foods before as well as offering the growing demand for online ordering services. Another added value is the consumer data it has from Whole Foods from the acquisition. Consumer shopping habits are useful tools for Amazon. Amazon can use habits and frequency of items to automatically reorder items and ship to customers doorstep. Amazon can also up sell and offer similar or complementary products. By understanding Amazons customers needs, Amazon is one step ahead.
Petro, G. (2017, Aug. 2). Amazons Acquisition of Whole Foods is About Two Things: Data and Product. Forbes.
Discussion Week #8: Bristol Myers Squibb/Celgene
Top of Form
On January 3, 2019, Bristol Myers Squibb announced that it was set to acquire Celgene, another pharmaceutical company. In doing so, Celgene ‘would be adding to the portfolio of pharmaceuticals with increased product differentiation for Bristol Myers Squibb. Daniel Strauss of Markets Insider stated that Bristol Myers Squibb will obtain “value creation opportunity” and “cost synergies”(2019) as well as Celgene’s strong financial contributions including a healthy balance sheet and strong returns. According to the New York Times, the deal will help both companies “advance their work in oncology, cardiovascular disease, immunology, and inflammation.” (2019) Squibb will also benefit from the acquisition by the innovation with which Celgene brings. The acquisition deal was expected to close in the 2019’s third quarter. It has yet to close and will most likely close late 2019 to early 2020.
Hsu, T. and Thomas, K. (2019, January). Bristol Myers to acquire Celgene, fortifying roster of cancer drugs. The New York Times, p. B2.
https://0-search-proquest-com.leopac.ulv.edu/docview/2162943641?accountid=25355
Strauss, D. (2019, June 24). Bristol-Myers Squibb is selling off a blockbuster drug to help its $74 billion merger with Celgene get approved-and now both stocks are tumbling.
https://markets.businessinsider.com/news/stocks/bristol-myers-squibb-celgene-stock-price-reaction-to-otezla-divestiture-2019-6-1028303108
